New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
08:26 EDTLLYEli Lilly upgraded at BMO Capital
As noted earlier, BMO Capital upgraded Eli Lilly to Market Perform from Underperform. The firm cited recent positive data for a number of the company's drugs, including its Bemaciclib cancer treatment, the upholding of the Alimta patent by a federal court, and low Street expectations for the company's Cymbalta and Evista as reasons for the upgrade. Target to $62 from $50.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
August 20, 2015
13:26 EDTLLYOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTLLYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information
August 18, 2015
10:01 EDTLLYEli Lilly says Humalog 200 units/mL KwikPen available in U.S. pharmacies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use